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BACKGROUND. Cancer of the corpus uteri occurs more commonly among white
women in the U.S., yet survival is poorer for black women. This study examined
whether this trend has changed and also examined the relation of age and histo-
logic subtype to differences in stage.
METHODS. This retrospective cohort study assessed incidence trends, mortality
trends, and the relation of age and histologic subtype to stage for 12,079 incident
cases and 2325 deaths registered between 1985 and 1994 in Michigan. Rate ratios
compared incidence and mortality. Odds ratios quantified the contribution of age
and histologic subtype to differences in risk for advanced stage, using Mantel–
Haenszel univariate techniques and multivariate logistic regression.
RESULTS. The overall incidence rate was 21.99 per 100,000, and the overall mor-
tality rate was 3.82 per 100,000. Black women had a 40% lower risk (rate ratio [RR]
5 0.60) of developing cancer of the corpus uteri but had a 54% greater risk (RR 5
1.54) of dying from cancer of the corpus uteri. Black women were at greater risk of
being diagnosed with either sarcoma or more aggressive adenocarcinoma. How-
ever, after adjustment for age and histologic subtype, black women still had an
increased risk for advanced stage disease (2.63, 95% confidence interval 5 2.19 –
3.16).
CONCLUSIONS. The disparity between white and black women persists in incidence
and mortality trends for cancer of the corpus uteri. The greater frequency of more
aggressive histologic subtypes experienced by black women accounts for only 10%
of their excess risk for more advanced stage disease. Cancer 1998;83:1546 –54.
© 1998 American Cancer Society.
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Cancer of the corpus uteri is the most common invasive gyneco-logic cancer occurring in women in the U.S., with an age-adjusted
incidence rate of 21.3 per 100,000 and an age-adjusted mortality rate
of 3.4 per 100,000.1 Of particular interest are the incidence and mor-
tality trends for this cancer, namely, that incidence is higher among
white women but mortality is higher among black women. Between
1988 and 1992, the age-adjusted incidence rate per 100,000 for white
women was 22.3, as compared with 14.8 for black women. However,
during the same time period, the age-adjusted mortality rate per
100,000 for black women was 6.0, compared with 3.2 for white
women. In addition, between 1986 and 1991 the 5-year relative sur-
vival rate for white women was 85%, but it was only 55.6% for black
women.1
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Several prognostic factors have been explored to
assess whether differences in the distribution of these
factors between black and white women can explain
the survival discrepancy. Compared with white
women, black women have poorer survival at age 65
years or older,1 have more advanced stage disease
when diagnosed,1–7 have fewer well-differentiated tu-
mors,2– 8 and have a higher frequency of more aggres-
sive histologic subtypes.3,6 – 8 However, in multivariate
analysis controlling for these factors, the survival dis-
parity persists.2– 4,7 Moreover, the disparity in stage
and poorer subsequent survival for black women does
not appear to be due to decreased access to health
care or delays in seeking treatment after initial symp-
tom recognition.3,8,9
Two types of endometrial cancer have been pro-
posed. Type I, or estrogen-dependent tumors, are
more common and less aggressive.10 –12 Type II, or
estrogen-independent tumors, are relatively uncom-
mon and appear to be more aggressive.10 –12 Using this
division, type II endometrial cancers and uterine sar-
comas together form a subgroup of more aggressive
uterine cancers. Recently, it has been suggested that
black women may experience a higher frequency of
more aggressive uterine cancers, and this would ex-
plain the more advanced stage and poorer prognosis.3
However, much of the research regarding differences
between black and white patients with this cancer has
excluded sarcomas, and many of the study popula-
tions evaluated have been too small to assess carefully
the racial differences among patients with uncommon
type II histologic subtypes of disease. This study was
undertaken to evaluate racial patterns for uterine can-
cer in relation to histologic subtype and stage at diag-
nosis. In this context, we have compared the incidence
and mortality trends in the state of Michigan for black
and white women with cancers of the corpus uteri
diagnosed during the years 1985–1994.
METHODS
Study Population and Eligibility
The study population was obtained from the Michigan
cancer incidence and all-cause mortality registries,
collected by the Cancer Surveillance Program of the
Michigan Department of Community Health. Eligibil-
ity for inclusion in the cancer incidence registry was
limited to newly diagnosed invasive cancers with the
“corpus uteri” topography described in the 1976 In-
ternational Classification of Diseases for Oncology
(ICD-0).13 From the mortality registry, eligibility was
limited to deaths of female residents of the state of
Michigan, where cause was coded as “malignant neo-
plasm of the corpus uteri” (codes 182.0 –182.8) or
“uterus, not otherwise specified” (code 179.0) using
the International Classification of Diseases, 9th revi-
sion.14 Since the 1980s, at least 75% of deaths from
cancer with a topography coded as “uterus, not oth-
erwise specified” have been subsequently confirmed
on medical record review to have been caused by
cancer of the uterine corpus.15 Overall, the study pop-
ulation included 11,146 white, 879 black, and 54
women of other races from the cancer incidence reg-
istry and 1986 white, 324 black, and 15 women of other
races from the mortality registry. To assess the racial
associations of interest, both incidence and mortality
data were selected to include only black or white
cases.
Variables
Covariates from the incidence registry were race, year
of diagnosis, histologic subtype, age group, and stage
at diagnosis. Stage was classified as localized (con-
fined to the organ of origin), regional (direct extension
to adjacent organs or tissues or lymph node involve-
ment), distant (spread to nonadjacent organs, distant
metastasis, or involvement of distant lymph nodes), or
unstaged.16 In addition, stage was collapsed into two
categories for fitting as a dichotomous outcome: ad-
vanced stage (regional or distant) and not advanced
stage (localized). A derived variable was constructed
for age, collapsing age into two groups: younger than
65 years and age 65 or older. The mean ages were
calculated using the midpoint of each 5-year age
group as each patient’s age. Histologic subtype was
classified using ICD-0, and derived variables were cre-
ated that collapsed subtypes into the following cate-
gories:17 1) adenocarcinoma, 2) adenoacanthoma, 3)
adenosquamous carcinoma, 4) clear cell adenocarci-
noma, 5) serous adenocarcinoma, 6) mucinous ade-
nocarcinoma, 7) epithelial (undifferentiated) carci-
noma, 8) squamous cell carcinoma, 9) all sarcomas,
and 10) other histology. In addition, based on previous
classifications of the aggressiveness of various histo-
logic subtypes,12,18 –20 categories were created for less
aggressive adenocarcinomas (adenocarcinoma, muci-
nous adenocarcinoma, adenoacanthoma, and adeno-
squamous adenocarcinoma), more aggressive adeno-
carcinomas (clear cell adenocarcinoma, serous
adenocarcinoma, squamous carcinoma, and undiffer-
entiated carcinoma), sarcomas, and other histology. A
second category for more aggressive adenocarcino-
mas was also created, with the subtype squamous
carcinoma dropped. Our concern was that, because
squamous carcinoma rarely occurs in its pure form,20
the squamous category might be subject to a high level
of misclassification due to either incomplete tumor
sampling or the presence of a cervical primary.
From the mortality registry, the variables age at
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death and race were included. As with incidence data,
age was divided into two groups: younger than 65
years and age 65 years or older.
Analysis/Statistical Methods
Cumulative incidence and mortality rates were calcu-
lated for 1985–1989 and 1990 –1994, and for the 10-
year period overall. For all rates, the denominator
used was the Michigan female population at the mid-
point of each time period (i.e., 1987 for the 1985–1989
rates, 1992 for the 1990 –1994 rates, and 1990 for the
overall rates21–23). All rates were age-adjusted, using
the direct method, to the 1970 U.S. population stan-
dard.24 Because the state registry data accounted for
95% of all incident cancer cases and virtually all can-
cer deaths that occurred in the Michigan population
between 1985 and 1994, confidence intervals (CIs) for
rates and ratios were not required.
All analyses were performed using the SAS (Statis-
tical Analysis Software) package (SAS Institute Inc.,
Cary, NC). Associations among race, age, histologic
subtype, and stage were first assessed by univariate
analysis using the Mantel–Haenszel chi-square test.
Stratified analyses were then performed using the
Mantel–Haenszel method, and the presence of inter-
action was assessed using the Breslow–Day test. Vari-
ables associated with stage in the univariate analysis
were subsequently included in a logistic regression
model to determine which factors were independent
predictors of stage. The significance of each model
was assessed with a likelihood ratio test. For odds
ratios obtained from logistic regression, 95% confi-
dence intervals were calculated. For Cochran–Mantel–
Haenszel odds ratios, corresponding 95% test-based
CIs were obtained. Differences between the mean ages
for each histologic subtype, overall and according to
race, were evaluated using nonparametric tests. Spe-
cifically, we used Wilcoxon’s rank sum test to analyze
ranks of data containing two levels and the Kruskal–
Wallis test to analyze ranks when more than two levels
were present.25
RESULTS
Incidence and Mortality Rates
The overall 10-year age-adjusted incidence rate for
cancer of the corpus uteri per 100,000 women was
21.99, and the overall age-adjusted mortality rate per
100,000 women was 3.82. The trends in incidence and
mortality rates are summarized in Table 1. Although
the overall age-adjusted incidence rate was relatively
stable between the two 5-year periods, the age-ad-
justed incidence rate per 100,000 increased for women
age 65 years or older from 97.67 in 1985–1989 to 103.07
in 1990 –1994, due primarily to an increasing inci-
dence for older white women. Incidence rates re-
mained relatively stable for black women. In compar-
ison to white women, black women had a 40% lower
risk (rate ratio [RR] 5 0.60) of developing cancer of the
corpus uteri.
Mortality rates per 100,000 improved for the most
recent 5 years, where rates decreased for both age
groups as well as for both race groups. For white
women, the decrease held for both age groups,
whereas for black women, only the older age group
experienced a decrease. In Michigan, black women
had 54% greater risk (RR 5 1.54) of dying, and this
excess risk increased during the most recent 5 years
(from 51% to 63%) due to an increase for younger
black women.
The age specific incidence rates by race for Mich-
igan compared with the U.S. SEER rates1 are presented
in Figure 1. The age specific incidence patterns in
Michigan during the years 1985–1994 tended to par-
allel those observed in the U.S. during 1988 –1992, and
the age-adjusted incidence rate per 100,000 was 21.99
in Michigan compared with 21.3 for the entire U.S.
Mortality rates in Michigan were also similar to those
in the U.S.; the overall age-adjusted mortality rate per
100,000 in Michigan during the 10-year study period
was 3.8, compared with 3.4 in the U.S. during the years
1988 –1992.1 Age specific mortality rates for Michigan
during the years 1985–1994 were compared with U.S.
SEER age-specific mortality rates for 1988 –1992 (Fig.
2). For each age specific group, the mortality rate in
Michigan was higher than that in the U.S. for white
women, especially for the older age groups. For black
women, the mortality rate in Michigan was lower than
that in the U.S., with the lower rates most pronounced
in the older age groups.
Variables Associated with Prognosis
The distribution by age (age ,65 years or $65 years)
did not differ between black and white women (Table
2). The distribution by stage at diagnosis in Michigan
was consistent with trends in the U.S.; black women,
compared with white women, were diagnosed with
more advanced stage disease. During the 10-year pe-
riod, only 49.4% of black women were diagnosed with
localized disease, compared with 68.5% of white wom-
en; and 17.6% of black women manifested distant
disease at diagnosis, compared with only 6.5% of
white women.
During the 10-year study period, the predominant
histologic subtypes for all races were adenocarcino-
mas. Black women had relatively fewer adenocarcino-
mas than white women (62.6% vs. 80.4%). In addition,
black women had fewer of the histologic variants of
adenocarcinoma known to be associated with a favor-
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able prognosis, including adenoacanthoma (0.7% vs.
3.0%) and mucinous adenocarcinoma (0.2% vs. 1.0%).
Black women had a greater proportion of adenocarci-
noma subtypes known to be associated with an unfa-
vorable prognosis, including clear cell (3.7% vs. 1.3%)
and serous (3.3% vs. 1.2%). Black women also had a
higher proportion of sarcomas than white women
(18.0% vs. 5.6%).
The mean age at diagnosis was significantly dif-
ferent across each of the four broad histologic sub-
types (Kruskal–Wallis chi-square 5 105.61, degrees of
freedom [df] 5 3, P 5 0.0001). Moreover, women with
more aggressive histologic subtypes were older than
women with less aggressive histologic subtypes (Wil-
coxon two-sample normal approximation z-statistic
standard score 5 9.67, P 5 0.0001). However, the
mean age at diagnosis by histologic subtype between
races did not differ, and an evaluation of the mean age
at diagnosis for each particular histologic subtype
demonstrated no differences between black and white
women for any of the subtypes (Wilcoxon two-sample
rank sum tests, P values ranged from 0.12 to 0.69).
Overall, more aggressive histologic subtypes were
associated with more advanced stages. Most notable,
however, was the pattern for black women. With the
exception of mucinous adenocarcinoma, the trend
was for black women to have more advanced stage
disease within each histologic subtype. However, be-
cause of the small numbers of black women in several
of these subgroups, only three of these trends reached
statistical significance (adenocarcinoma, P 5 0.001;
adenosquamous carcinoma, P , 0.05; sarcoma, P ,
0.05).
Mantel–Haenszel chi-square tests conducted to
evaluate associations between race and the prognostic
factors confirmed the trends presented in Table 2. Age
at diagnosis did not differ between black and white
women. However, compared with white women, black
TABLE 1
Age-Adjusted Incidence and Mortality Rates for Cancer of the Corpus Uteri, by Race, for Michigan Residents,
1985–1994a





All ages 21.99 23.22 13.95 0.60
Age ,65 yrs 13.48 14.44 7.68 0.53
Age $65 yrs 99.61 103.34 71.12 0.69
1985–1989
No. (%) 5754 5322 (92.5%) 412 (7.2%)
All ages 21.51 22.50 14.12 0.63
Age ,65 yrs 13.16 13.93 7.68 0.55
Age $65 yrs 97.67 100.76 72.89 0.72
1990–1994
No. (%) 6325 5824 (92.1%) 467 (7.4%)
All ages 22.35 23.58 14.17 0.60
Age ,65 yrs 13.51 14.44 7.71 0.53
Age $65 yrs 103.07 107.01 73.15 0.68
Mortality
All yrs (1985–1994)
All ages 3.82 3.61 5.55 1.54
Age ,65 yrs 1.43 1.34 2.08 1.55
Age $65 yrs 25.67 24.38 37.27 1.53
1985–1989
No. (%) 1180 1009 (85.5%) 167 (14.2%)
All ages 3.98 3.79 5.74 1.51
Age ,65 yrs 1.53 1.46 2.07 1.42
Age $65 yrs 26.34 25.06 39.18 1.56
1990–1994
No. (%) 1175 977 (83.1%) 187 (15.9%)
All ages 3.66 3.41 5.57 1.63
Age ,65 yrs 1.30 1.17 2.10 1.79
Age $65 yrs 25.19 23.78 37.23 1.57
a Rates are per 100,000 and are age-adjusted, using the direct method, to the 1970 U.S. standard population.
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women were two and one-half times more likely to
present with advanced stage disease, two and one-half
times more likely to present with more aggressive
adenocarcinomas, and three and one-half times more
likely to present with sarcomas (Table 3). When the
analysis was repeated with the subtype of squamous
carcinoma dropped from the category of more aggres-
sive adenocarcinomas, the results were virtually iden-
tical. Black women were still two and one-half times
more likely to present with more aggressive adenocar-
cinomas (odds ratio [OR] 5 2.55, 95% CI 5 2.08–3.12).
Age-adjusted incidence rates per 100,000 were
calculated to compare absolute numbers of histologic
subtypes occurring in black and white women. The
incidence rate per 100,000 of less aggressive adeno-
carcinomas was 20.52 for white women and 9.39 for
black women (black:white [B:W] RR 5 0.46). For more
aggressive adenocarcinomas, the rate per 100,000 was
1.29 for white women and 1.84 for black women (B:W
RR 5 1.43); for sarcomas, the rate per 100,000 was 1.28
for white women and 2.48 for black women (B:W RR 5
1.94); and for other subtypes, the rate per 100,000 was
FIGURE 1. Age specific incidence,
rates by race, uterine corpus cancer,
U.S. SEER, 1988–92, and Michigan,
1985–94.
FIGURE 2. Age specific mortality,
rates by race, uterine corpus cancer,
U.S. SEER, 1988–92, and Michigan,
1985–94.
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0.15 for white women and 0.24 for black women (B:W
RR 5 1.60).
To compare absolute numbers of stage at diagno-
sis (advanced vs. localized) for black and white
women, age-adjusted incidence rates per 100,000 were
calculated. For localized stage disease, the rate per
100,000 was 16.16 for white women and 6.90 for black
women (B:W RR50.43). For advanced stage disease,
the rate per 100,000 was 4.46 for white women and
5.60 for black women (B:W RR 5 1.26).
Age at diagnosis and histologic subtype were both
associated with stage at diagnosis. Older women were
more likely to present with advanced stage disease
(chi-square 5 80.64, df 5 1, P 5 0.001). Women with
more aggressive adenocarcinomas, sarcomas, and his-
tologic subtypes classified as “other” were more likely
to present with advanced stage disease (chi-square 5
348.98, df 5 1, P 5 0.001) than women with less
aggressive adenocarcinomas. A significant interaction
between race and a combined variable for all histo-
logic subtypes representing more aggressive tumors
was found that modified the association between his-
tologic subtype and advanced stage (Breslow–Day chi-
square 5 5.23, df 5 1, P 5 0.02). After a separate
assessment of each subtype for any interaction with
race, a borderline significant interaction was found
between more aggressive adenocarcinomas and race
(Breslow–Day chi-square 5 3.375, df 5 1, P 5 0.07).
Specifically, the risk of advanced stage disease, given a
histologic subtype of more aggressive adenocarcino-
mas compared with less aggressive adenocarcinomas,
was greater for white women (OR 5 3.42, P , 0.001)
than for black women (OR 5 2.22, P , 0.001). Con-
versely, advanced stages were exhibited more fre-
quently for black women with less aggressive adeno-
carcinomas.
The logistic regression modeling strategy involved
several steps (Table 4). The crude association was first
estimated, then other prognostic factors found to be
associated with advanced stage in univariate analyses
were added to evaluate whether the crude association
changed. When both age and histologic subtype were
added simultaneously, the risk of advanced stage for
black women decreased (OR 5 2.37, P , 0.0001); and
based upon the likelihood ratio (LR) test, this was the
best model. Although the model that included race,
age, histologic subtype, and the interaction between
race and histologic subtype was not statistically supe-
rior to the model without the interaction term based
on the likelihood ratio test (LR 5 4.52, df 5 3, P .
0.10), the magnitude of the OR changed significantly
when the interaction term was included. Therefore,
the final accepted model was the one that adjusted for
age, histologic subtype, and the interaction between
race and histologic subtype, where black women had a
risk of presenting with advanced stage disease that
was over two and one-half times the risk for white
women (OR 5 2.63, 95% CI 5 2.19 –3.16). Results were
identical when the subtype squamous carcinoma was
dropped from the “more aggressive adenocarcino-
mas” category and the final model was run again
(OR 5 2.67).
DISCUSSION
U.S. SEER data has demonstrated that cancer of the
corpus uteri occurs more commonly among white
women, yet 5-year relative survival within each stage
of disease is poorer and age-adjusted mortality is
higher for black women.1 Several clinic-based2,5 and
population-based4,7 studies of incident cases from the
1970s and 1980s have documented a lower survival
rate for black women with cancer of the corpus uteri.
To explore whether black-white patterns for incidence
and mortality from cancer of the corpus uteri were
changing, we compared incidence and mortality in the
1990s with incidence and mortality in the 1980s. In the
1990s, incidence for white women, especially those
age 65 years or older, increased by 6.2%. Overall mor-
tality rates decreased slightly for both races, although
mortality rates for black women younger than 65 years
did not change. This represents a reversal of the trends
from the 1970s and 1980s. Specifically, U.S. SEER data
collected between 1973 and 1987 for cancer of the
TABLE 2
Summary of Age and Tumor Characteristics for Cancer of the Corpus










,65 yrs 5661 (46.9) 5220 (46.8) 407 (46.3) 34 (63.0)
$65 yrs 6418 (53.1) 5926 (53.2) 472 (53.7) 20 (37.0)
Stage at diagnosis
Localized 8103 (67.1) 7635 (68.5) 434 (49.4) 34 (63.0)
Regional 1689 (14.0) 1478 (13.3) 198 (22.5) 13 (24.1)
Distant 886 (7.3) 728 (6.5) 155 (17.6) 3 (5.5)
Unstaged 1401 (11.6) 1305 (11.7) 92 (10.5) 4 (7.4)
Histologic subtype
Adenocarcinoma 9559 (79.1) 8970 (80.4) 550 (62.6) 39 (72.2)
Adenoacanthoma 337 (2.8) 330 (3.0) 6 (0.7) 1 (1.9)
Adenosquamous 411 (3.4) 380 (3.4) 29 (3.3) 2 (3.7)
Clear cell 184 (1.6) 150 (1.3) 33 (3.7) 1 (1.8)
Serous 165 (1.4) 134 (1.2) 29 (3.3) 2 (3.7)
Mucinous 110 (0.9) 107 (1.0) 2 (0.2) 1 (1.9)
Undifferentiated
carcinoma 320 (2.6) 286 (2.6) 34 (3.9) 0 (0.0)
Squamous carcinoma 121 (1.0) 98 (0.9) 23 (2.6) 0 (0.0)
Sarcomas (all) 794 (6.6) 629 (5.6) 158 (18.0) 7 (13.0)
Other 78 (0.6) 62 (0.6) 15 (1.7) 1 (1.8)
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corpus uteri demonstrated stable incidence for black
women but a decrease in incidence for white women
from 30.8 to 23.0 per 100,000.26 Moreover, from the
1970s to the 1980s, U.S. SEER data demonstrated con-
sistent decreases in age-specific mortality rates from
cancer of the corpus uteri for black and white
women.1
The recent shift in incidence and mortality trends,
in which incidence has increased proportionately
more for white women but mortality has decreased
proportionately less for black women, may be due to
differences in the distribution of several factors that
may affect risk, including socioeconomic status and
cultural factors associated with access to and quality
of preventive practices and medical care, as well as
life-style risk factors.27 The increase in the incidence
rate from 100.76 during the years 1985–1989 to 107.01
during the years 1990 –1994 for white women age 65
years or older was probably not due solely to increased
exposure to unopposed estrogen-replacement therapy
(ERT).28 A conclusion of the Postmenopausal Estro-
gen/Progestin Interventions (PEPI) Trial was that phy-
sicians should give serious consideration to the addi-
tion of progestin when administering ERT to
postmenopausal women with an intact uterus;29 in
addition, it has been noted that progestins are now
generally added to estrogen regimens given to women
(without prior hysterectomy) to reduce the risk of
endometrial cancer associated with unopposed estro-
gen therapy.28 However, the increase in incidence
warrants increased clinical surveillance of older high
risk white women to identify uterine cancers at the
earliest stage possible.
Like the authors of other reports,28,30 –32 we ob-
served an association between older age at diagnosis
and the incidence and percentage frequency of more
aggressive histologic subtypes, including clear cell ad-
enocarcinoma, serous adenocarcinoma, and undiffer-
entiated carcinoma. The increase in more aggressive
histologic subtypes occurring in older women may be
accompanied by the accumulation of genetic muta-
tions that are expressed in estrogen-independent tu-
mor progression. For example, p53 abnormalities have
been demonstrated in 86% of serous adenocarcino-
mas, compared with only 20% of endometrioid ade-
nocarcinomas.10 For other aggressive histologic sub-
types, consistent molecular genetic and epigenetic
alterations have yet to be identified. There were no
differences between blacks and whites in mean age at
diagnosis, either within each histologic subtype or
across subtypes.
TABLE 3
Summary of Univariate Analyses of Age and Tumor Characteristics for Cancer of the Corpus Uteri, by Race,










,65 yrs 46.9 46.3 Reference
$65 yrs 53.2 53.7 1.02 (0.90–1.16)
Stage at diagnosis
Not advanced 68.5 49.4 Reference
Advanced 19.8 40.1 2.57 (2.25–2.92)
No. of patientsa 9841 787
Histologic subtype
Less aggressive adenocarcinomas 87.8 66.8 Reference
More aggressive adenocarcinomas 6.0 13.5 2.67 (2.23–3.21)
Sarcomas 5.6 18.0 3.55 (3.03–4.16)
Other 0.6 1.7 3.44 (2.16–5.49)
a No. of patients is indicated only when patients have been excluded because of missing data.
TABLE 4
Summary of Logistic Regression Modeling of Significant Predictors of
Advanced Stage Disease for Cancer of the Corpus Uteri in Black







vs. white); P value
1. Race alone 11,556.009 (df 5 1) 2.82 ,0.0001
2. Race and age ($65 yrs) 11,474.537 (df 5 2) 2.83 ,0.0001
3. Race and histology 11,297.79 (df 5 4) 2.36 ,0.0001
4. Race, age, and histology 11,225.643 (df 5 5) 2.37 ,0.0001
5. Race, age, histology, and
interaction between race
and histology 11,221.12 (df 5 8) 2.63 ,0.0001
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Our results were consistent with data for the U.S.,1
in that stage was more advanced for black women.
Black women also had higher proportions of more
aggressive histologic subtypes, including clear cell ad-
enocarcinomas, serous adenocarcinomas, and sarco-
mas, and their risk of presenting with more aggressive
histologic subtypes was between two and one-half to
three and one-half times greater. Like the authors of a
recent, similar study,33 we observed that the incidence
rate per 100,000 of the relatively infrequent but more
aggressive subtypes of endometrial carcinoma was
similar between black (1.84) and white (1.29) women,
and that the 40% decrease in age-adjusted incidence
among black women was due to a lower absolute risk
of 11 cases per 100,000 for less aggressive histologic
subtypes.
In our multivariate model, black women still had a
risk of advanced stage disease two and one-half times
greater than that of white women. A notable finding
was that black women were more likely to have more
advanced stage disease within each histologic sub-
type; this brings into question the inference that the
increased frequency of advanced stage disease in
black women is primarily a consequence of experienc-
ing more aggressive histologic subtypes. Moreover, we
observed a difference in the incidence rate per 100,000
of advanced stage disease at diagnosis between black
(5.60) and white (4.46) women, likewise suggesting a
higher absolute risk of advanced stage disease for
black women.
Because of our concern that sarcomas may have a
different association with to stage at diagnosis than
endometrial carcinomas, we repeated the multivariate
analysis and excluded women with sarcomas. The re-
sults were completely identical in terms of our analytic
predictive Model 5 (OR 2.63, P , 0.0001, LR statistic
10293.180, df 5 6), and the only noteworthy difference
was for Model 4 (race, age, and histology), where the
risk of advanced stage for black women compared
with white women increased from 2.37 to 2.47 when
sarcomas were excluded.
Although this study was able to assess several
prognostic factors for cancer of the corpus uteri and
the differences in these factors between black and
white women, there were some limitations. In calcu-
lating incidence rates, the denominator should only
include the population at risk. Because the rate of
hysterectomy has been shown to be as high as 35% for
women age 60 or older,34 including all of the female
population in Michigan in the denominator resulted
in underestimation of the incidence rates. However,
SEER incidence rates were also based on the entire
female population in specific regions of the U.S.
The structure and content of the registry data also
imposed limitations. One significant limitation was
the inability to link cancer incidence with all-cause
mortality, making it impossible to evaluate the prog-
nostic effect of stage at diagnosis or histologic subtype
on racial differences in mortality. In addition, tumor
grade was not included in the registry data, eliminat-
ing our ability to include this important prognostic
variable in our analyses. However, we likely would
have found tumor grade to be highly correlated with
our category of more aggressive adenocarcinomas.
This category was comprised of clear cell, serous, and
undifferentiated carcinomas; these are typically high
grade lesions19,33,35 for which grading is based on nu-
clear grade rather than architectural grade, and they
are, in fact, frequently ungraded.31,36
This study also had several strengths. The sample
size was large, allowing for adequate stratification of
the data without compromising the total numbers of
cases in each subdivision. In addition, because the
data were obtained from a large population-based
registry, which contained information on all incident
cases of cancer of the corpus uteri and all deaths
attributed to cancer of the corpus uteri in the state of
Michigan, it should be possible to apply the results
generally to other U.S. states that have similar socio-
demographic distributions.
We were able to conduct a comprehensive evalu-
ation of black-white differences by histologic subtype
in the context of evaluating differences in stage be-
tween black and white women. We demonstrated that,
although black women experienced a greater fre-
quency of adverse histopathologic features, including
sarcomas, these more aggressive forms of cancer of
the corpus uteri accounted for only 10% of the excess
risk for advanced stage disease at diagnosis for black
women (using the formula 5RRunadjusted 2 RRadjusted 6 /
5RRunadjusted 2 1.0637). In fact, the interaction term
demonstrated that histologic subtype was more pre-
dictive of advanced stage disease for white women
than it was for black women. This suggests that there
are other important determinants of stage for black
women. The intuitive hypothesis for explaining these
differences is that black women may have less access
to care on symptom recognition or may delay seeking
treatment after the onset of symptoms. However,
studies conducted to evaluate delay in seeking treat-
ment have not found significant differences between
black and white women.3,8,9 Perhaps other correlates
or predictors of advanced stage or of mortality among
black women should be explored, such as the molec-
ular determinants of multistep progression of the can-
cer; life-style and psychosocial risk factors, including
comorbidity at the time of diagnosis; and barriers to
access and utilization of optimal health care.
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